Top 50 Global Pharmaceutical Organization Awards Fourth EDC Study to eResearchTechnology

Top 50 Global Pharmaceutical Organization Awards Fourth EDC Study to
eResearchTechnology
Total Program Level Award Includes More Than 80 Sites Throughout the U.S. 


PHILADELPHIA, March 25  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading e-research technology and services provider, announced today
that it has been awarded the fourth in a series of electronic data capture (EDC)
studies from a top 50 global pharmaceutical organization for one of its key
drugs in clinical trials.

The total award covers a program of two Phase II and two Phase III studies that
are being conducted at more than 80 research sites distributed across the U.S. 
The sponsor is leveraging eRT's enterprise EDC solution, which provides for
rapid study set-up, validation and deployment, along with the ability to easily
aggregate data across multiple trials for program level analysis.  In addition,
the sponsor has elected eRT's site support services, which are designed to
support the process of qualifying and initiating investigator sites in use of
eRT's EDC solution, along with support for site personnel in use of the EDC
system throughout the study process.

"eRT's enterprise EDC capabilities are key to this organization's ability to
deploy four EDC studies in a four-month period," said Scott Grisanti, senior
vice president of business development and chief marketing officer at eRT. 
"Further, the roll-out of this EDC program provides an excellent illustration of
eRT's knowledge and technology transfer program.  eRT's enterprise EDC platform
has been successfully implemented within the client's computing infrastructure,
and client staff have been fully trained and are performing all study
configuration activities."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The studies pertaining to these awards may be canceled by the sponsor
at its sole discretion.  As a result, actual results may differ materially from
any financial outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in the company's
Reports on Forms 10-K and 10-Q filed with the Securities and Exchange
Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright